New Marker Identifies Alzheimer’s
Canadian researchers have found clear evidence that increases in the size of the brain ventricles are directly associated with cognitive impairment and Alzheimer’s disease.
Ventricles are fluid-filled cavities in the brain. The research, led by Robarts scientist Robert Bartha, shows the volume of the brain ventricles expands as surrounding tissue dies.
The research was published online today in the neurology journal Brain.
Currently, diagnosis for Alzheimer’s relies on neuro-cognitive assessments, such as testing of memory, ability to problem solve, count, etc. Definitive diagnosis is not possible until after death when an autopsy can reveal the presence of amyloid plaques and ‘tangles’ in brain tissue.
Previous research has shown the link between ventricle size and Alzheimer’s over longer time intervals. The research conducted at Robarts Research Institute shows that ventricle size increases with mild cognitive impairment before a diagnosis of Alzheimer’s disease, and continues to increase with the onset and progression of Alzheimer’s disease after only six months.
“These findings mean that, in the future, by using magnetic resonance imaging (MRI) to measure changes in brain ventricle size, we may be able to provide earlier and more definitive diagnosis,” said Bartha, who is also an Associate Professor in the Schulich School of Medicine & Dentistry in Medical Biophysics.
“In addition, as new treatments for Alzheimer’s are developed, the measurement of brain ventricle changes can also be used to quickly determine the effectiveness of the treatment.”
Researchers analyzed 500 data sets of MRI scans among individuals at baseline and six months later. The review discovered Alzheimer’s patients with a genetic marker for Alzheimer’s disease exhibited faster expansion in ventricle volume.
The images were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a large multi-site trial sponsored by the National Institutes of Health in the United States and the pharmaceutical industry. The project includes an online database of imaging information gathered from 800 people at more than 50 sites across the U.S. and Canada.
The images are MRIs of individuals with no cognitive impairment, those with mild cognitive impairment and people with Alzheimer’s disease. The database can be used by any primary researcher.
“This is one of the first major research studies published using data from ADNI”, said Borrie, “but there will be many more neuroimaging and biomarker discoveries to arise from the ADNI project.
It is a tremendous opportunity for researchers anywhere in the world to use the ADNI databases, to collaborate and share their findings in a new way that will move Alzheimer’s disease research forward more quickly, objectively and effectively. Already we are building new international collaborations, arising from ADNI, that we could not have even imagined.”
Nauert PhD, R. (2015). New Marker Identifies Alzheimer’s. Psych Central. Retrieved on January 20, 2017, from http://psychcentral.com/news/2008/07/11/new-marker-to-identify-alzheimers/2593.html